347 related articles for article (PubMed ID: 30939096)
1. Seven-Year Follow-Up Analysis of Adjuvant Paclitaxel and Trastuzumab Trial for Node-Negative, Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.
Tolaney SM; Guo H; Pernas S; Barry WT; Dillon DA; Ritterhouse L; Schneider BP; Shen F; Fuhrman K; Baltay M; Dang CT; Yardley DA; Moy B; Marcom PK; Albain KS; Rugo HS; Ellis MJ; Shapira I; Wolff AC; Carey LA; Overmoyer B; Partridge AH; Hudis CA; Krop IE; Burstein HJ; Winer EP
J Clin Oncol; 2019 Aug; 37(22):1868-1875. PubMed ID: 30939096
[TBL] [Abstract][Full Text] [Related]
2. Cardiac Outcomes of Patients Receiving Adjuvant Weekly Paclitaxel and Trastuzumab for Node-Negative, ERBB2-Positive Breast Cancer.
Dang C; Guo H; Najita J; Yardley D; Marcom K; Albain K; Rugo H; Miller K; Ellis M; Shapira I; Wolff AC; Carey LA; Moy B; Groarke J; Moslehi J; Krop I; Burstein HJ; Hudis C; Winer EP; Tolaney SM
JAMA Oncol; 2016 Jan; 2(1):29-36. PubMed ID: 26539793
[TBL] [Abstract][Full Text] [Related]
3. Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer.
Tolaney SM; Barry WT; Dang CT; Yardley DA; Moy B; Marcom PK; Albain KS; Rugo HS; Ellis M; Shapira I; Wolff AC; Carey LA; Overmoyer BA; Partridge AH; Guo H; Hudis CA; Krop IE; Burstein HJ; Winer EP
N Engl J Med; 2015 Jan; 372(2):134-41. PubMed ID: 25564897
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of ABP 980 compared with reference trastuzumab in women with HER2-positive early breast cancer (LILAC study): a randomised, double-blind, phase 3 trial.
von Minckwitz G; Colleoni M; Kolberg HC; Morales S; Santi P; Tomasevic Z; Zhang N; Hanes V
Lancet Oncol; 2018 Jul; 19(7):987-998. PubMed ID: 29880292
[TBL] [Abstract][Full Text] [Related]
5. Phase II Study of Weekly Paclitaxel with Trastuzumab and Pertuzumab in Patients with Human Epidermal Growth Receptor 2 Overexpressing Metastatic Breast Cancer: 5-Year Follow-up.
Wang R; Smyth LM; Iyengar N; Chandarlapaty S; Modi S; Jochelson M; Patil S; Norton L; Hudis CA; Dang CT
Oncologist; 2019 Aug; 24(8):e646-e652. PubMed ID: 30602614
[TBL] [Abstract][Full Text] [Related]
6. Dose-dense adjuvant chemotherapy in HER2-positive early breast cancer patients before and after the introduction of trastuzumab: Exploratory analysis of the GIM2 trial.
Lambertini M; Poggio F; Bruzzone M; Conte B; Bighin C; de Azambuja E; Giuliano M; De Laurentiis M; Cognetti F; Fabi A; Bisagni G; Durando A; Turletti A; Urracci Y; Garrone O; Puglisi F; Montemurro F; Ceppi M; Del Mastro L;
Int J Cancer; 2020 Jul; 147(1):160-169. PubMed ID: 31724170
[TBL] [Abstract][Full Text] [Related]
7. Intrinsic Subtype and Therapeutic Response Among HER2-Positive Breaty st Tumors from the NCCTG (Alliance) N9831 Trial.
Perez EA; Ballman KV; Mashadi-Hossein A; Tenner KS; Kachergus JM; Norton N; Necela BM; Carr JM; Ferree S; Perou CM; Baehner F; Cheang MC; Thompson EA
J Natl Cancer Inst; 2017 Feb; 109(2):. PubMed ID: 27794124
[TBL] [Abstract][Full Text] [Related]
8. Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831.
Perez EA; Romond EH; Suman VJ; Jeong JH; Sledge G; Geyer CE; Martino S; Rastogi P; Gralow J; Swain SM; Winer EP; Colon-Otero G; Davidson NE; Mamounas E; Zujewski JA; Wolmark N
J Clin Oncol; 2014 Nov; 32(33):3744-52. PubMed ID: 25332249
[TBL] [Abstract][Full Text] [Related]
9. Trastuzumab in combination with weekly paclitaxel and carboplatin as neo-adjuvant treatment for HER2-positive breast cancer: The TRAIN-study.
van Ramshorst MS; van Werkhoven E; Mandjes IAM; Schot M; Wesseling J; Vrancken Peeters MTFD; Meerum Terwogt JM; Bos MEM; Oosterkamp HM; Rodenhuis S; Linn SC; Sonke GS
Eur J Cancer; 2017 Mar; 74():47-54. PubMed ID: 28335887
[TBL] [Abstract][Full Text] [Related]
10. Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Chan A; Delaloge S; Holmes FA; Moy B; Iwata H; Harvey VJ; Robert NJ; Silovski T; Gokmen E; von Minckwitz G; Ejlertsen B; Chia SKL; Mansi J; Barrios CH; Gnant M; Buyse M; Gore I; Smith J; Harker G; Masuda N; Petrakova K; Zotano AG; Iannotti N; Rodriguez G; Tassone P; Wong A; Bryce R; Ye Y; Yao B; Martin M;
Lancet Oncol; 2016 Mar; 17(3):367-377. PubMed ID: 26874901
[TBL] [Abstract][Full Text] [Related]
11. Long-Term Survival Analysis of Adjuvant Chemotherapy with or without Trastuzumab in Patients with T1, Node-Negative HER2-Positive Breast Cancer.
He X; Ji J; Tian M; Esteva FJ; Hortobagyi GN; Yeung SJ
Clin Cancer Res; 2019 Dec; 25(24):7388-7395. PubMed ID: 31515457
[TBL] [Abstract][Full Text] [Related]
12. NSABP B-47/NRG Oncology Phase III Randomized Trial Comparing Adjuvant Chemotherapy With or Without Trastuzumab in High-Risk Invasive Breast Cancer Negative for HER2 by FISH and With IHC 1+ or 2.
Fehrenbacher L; Cecchini RS; Geyer CE; Rastogi P; Costantino JP; Atkins JN; Crown JP; Polikoff J; Boileau JF; Provencher L; Stokoe C; Moore TD; Robidoux A; Flynn PJ; Borges VF; Albain KS; Swain SM; Paik S; Mamounas EP; Wolmark N
J Clin Oncol; 2020 Feb; 38(5):444-453. PubMed ID: 31821109
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness of neo-adjuvant systemic therapy with trastuzumab for basal HER2 type breast cancer: results from retrospective cohort study of Japan Breast Cancer Research Group (JBCRG)-C03.
Sagara Y; Takada M; Ohi Y; Ohtani S; Kurozumi S; Inoue K; Kosaka Y; Hattori M; Yamashita T; Takao S; Sato N; Iwata H; Kurosumi M; Toi M
Breast Cancer Res Treat; 2018 Oct; 171(3):675-683. PubMed ID: 29971625
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: final 10-year analysis of the open-label, single-arm, phase 2 APT trial.
Tolaney SM; Tarantino P; Graham N; Tayob N; Parè L; Villacampa G; Dang CT; Yardley DA; Moy B; Marcom PK; Albain KS; Rugo HS; Ellis MJ; Shapira I; Wolff AC; Carey LA; Barroso-Sousa R; Villagrasa P; DeMeo M; DiLullo M; Zanudo JGT; Weiss J; Wagle N; Partridge AH; Waks AG; Hudis CA; Krop IE; Burstein HJ; Prat A; Winer EP
Lancet Oncol; 2023 Mar; 24(3):273-285. PubMed ID: 36858723
[TBL] [Abstract][Full Text] [Related]
15. Survival Analysis After Neoadjuvant Chemotherapy With Trastuzumab or Lapatinib in Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in the GeparQuinto (G5) Study (GBG 44).
Untch M; von Minckwitz G; Gerber B; Schem C; Rezai M; Fasching PA; Tesch H; Eggemann H; Hanusch C; Huober J; Solbach C; Jackisch C; Kunz G; Blohmer JU; Hauschild M; Fehm T; Nekljudova V; Loibl S;
J Clin Oncol; 2018 May; 36(13):1308-1316. PubMed ID: 29543566
[TBL] [Abstract][Full Text] [Related]
16. Benefit of adjuvant chemotherapy with or without trastuzumab in pT1ab node-negative human epidermal growth factor receptor 2-positive breast carcinomas: results of a national multi-institutional study.
de Nonneville A; Gonçalves A; Zemmour C; Classe JM; Cohen M; Lambaudie E; Reyal F; Scherer C; Muracciole X; Colombo PE; Giard S; Rouzier R; Villet R; Chopin N; Darai E; Garbay JR; Gimbergues P; Sabiani L; Coutant C; Sabatier R; Bertucci F; Boher JM; Houvenaeghel G
Breast Cancer Res Treat; 2017 Apr; 162(2):307-316. PubMed ID: 28155054
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of Neoadjuvant Chemotherapy with Epirubicin and Cyclophosphamide and Weekly Paclitaxel and Trastuzumab in Human Epidermal Growth Factor Receptor 2-Positive Breast Carcinoma: A Real-World Study.
Zhang M; Li L; Zhang S; Zhu W; Yang S; Di G; Ma X; Yang H
Biomed Res Int; 2020; 2020():3208391. PubMed ID: 32461977
[TBL] [Abstract][Full Text] [Related]
18. Local-regional recurrence in women with small node-negative, HER2-positive breast cancer: results from a prospective multi-institutional study (the APT trial).
Bellon JR; Guo H; Barry WT; Dang CT; Yardley DA; Moy B; Marcom PK; Albain KS; Rugo HS; Ellis M; Wolff AC; Carey LA; Overmoyer BA; Partridge AH; Hudis CA; Krop I; Burstein HJ; Winer EP; Tolaney SM
Breast Cancer Res Treat; 2019 Jul; 176(2):303-310. PubMed ID: 31004299
[TBL] [Abstract][Full Text] [Related]
19. UCBG 2-04: Long-term results of the PACS 04 trial evaluating adjuvant epirubicin plus docetaxel in node-positive breast cancer and trastuzumab in the human epidermal growth factor receptor 2-positive subgroup.
D'Hondt V; Canon JL; Roca L; Levy C; Pierga JY; Le Du F; Campone M; Desmoulins I; Goncalves A; Debled M; Rios M; Ferrero JM; Serin D; Hardy-Bessard AC; Piot G; Brain E; Dohollou N; Orfeuvre H; Lemonnier J; Roché H; Delaloge S; Dalenc F
Eur J Cancer; 2019 Nov; 122():91-100. PubMed ID: 31634648
[TBL] [Abstract][Full Text] [Related]
20. Cardiac Safety of Paclitaxel Plus Trastuzumab and Pertuzumab in Patients With HER2-Positive Metastatic Breast Cancer.
Yu AF; Manrique C; Pun S; Liu JE; Mara E; Fleisher M; Patil S; Jones LW; Steingart RM; Hudis CA; Dang CT
Oncologist; 2016 Apr; 21(4):418-24. PubMed ID: 26984450
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
